Journal
Theranostics
Publication Date
2019
Volume
9
Issue
8
Inclusive Pages
2129-2142
Document Type
Open Access Publication
DOI
10.7150/thno.31179
Rights and Permissions
Timmermand OV, Elgqvist J, Beattie KA, Örbom A, Larsson E, Eriksson SE, Thorek DLJ, Beattie BJ, Tran TA, Ulmert D, Strand SE. Preclinical efficacy of hK2 targeted [177Lu]hu11B6 for prostate cancer theranostics. Theranostics 2019; 9(8):2129-2142. doi:10.7150/thno.31179. Available from http://www.thno.org/v09p2129.htm This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Recommended Citation
Timmermand, Oskar Vilhelmsson; Elgqvist, Jörgen; Beattie, Kai A.; Örbom, Anders; Larsson, Erik; Eriksson, Sophie E.; Thorek, Daniel L. J.; Beattie, Bradley J.; Tran, Thuy A.; Ulmert, David; and Strand, Sven-Erik, "Preclinical efficacy of hK2 targeted [177Lu]hu11B6 for prostate cancer theranostics." Theranostics. 9, 8. 2129-2142. (2019).
https://digitalcommons.wustl.edu/open_access_pubs/7793
